Atreca has raised $91m to step up research and development around the fresh approach to drug discovery that is continuing to attract attention. The company has received $125m through venture capital rounds in recent years, investors including GlaxoSmithKline and the Bill & Melinda Gates Foundation supporting its method of probing the B-cell responses to identify novel antibodies and the targets that engage with them. The latest series C round was led by an anonymous "large US-based healthcare-focused fund" that has bankrolled Atreca's rise. Existing backers Wellington Management and Cormorant Asset Management contributed, with several new investors also coming aboard.
Atreca has raised $125m to step up research and development around the fresh approach to drug discovery that is continuing to attract attention. The company has received $91m through venture capital rounds in recent years, investors including GlaxoSmithKline and the Bill & Melinda Gates Foundation supporting its method of probing the B-cell responses to identify novel antibodies and the targets that engage with them. The latest series C round was led by an anonymous "large US-based healthcare-focused fund" that has bankrolled Atreca's rise. Existing backers Wellington Management and Cormorant Asset Management contributed, with several new investors also coming aboard.